Chalcogen Or Nitrogen Bonded Indirectly To The Imidazole Ring By Nonionic Bonding Patents (Class 514/399)
-
Patent number: 8569352Abstract: Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: GrantFiled: June 26, 2006Date of Patent: October 29, 2013Assignee: Exelixis Patent Company LLCInventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao-Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
-
Publication number: 20130274306Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.Type: ApplicationFiled: May 22, 2013Publication date: October 17, 2013Inventors: Pierre ATTALI, Caroline LEMARCHAND, Vanessa ROULET, Claire SCHEUIR, Lorraine ZAKIN
-
Patent number: 8541598Abstract: This invention relates to ionic liquid (ILs) solvents for chemical synthesis based on an alkyl-imidazolium cation core containing ionic liquids which have enhanced biodegradability and reduced toxicity relative to existing imidazolium bases ILs such as 1-butyl-3-methylimidazolium (bmmim) salts. Many of the described ILs produce a score of over 60% biodegradability over 28 days in a biodegradability test such as the Sturm Test, the Closed Bottle Test (OECD 301D) or the CO2 Headspace Test (ISO 14593). The ILs of the invention comprise an alkyl substituted imidazolium cationic core having a —C?OX— side chain in the 3-position of the imidazole ring, wherein X?O, NH, N or S and an associated counteranion characterized in that the —C?OX side chain comprises at least one ether linkage. The biodegradable and non-toxic IL may be used as green solvents for the chemical, pharmaceutical, biofuel and biomass industries. The ILs of the invention are particularly useful in hydrogenation, pericyclic and metathesis reactions.Type: GrantFiled: August 21, 2008Date of Patent: September 24, 2013Assignee: Dublin City UniversityInventors: Nick Gathergood, Saibh Morrissey, Bruce Pegot
-
Publication number: 20130245079Abstract: The use of polyhexamethylene guanidine hydrochloride as preservative for preventing and controlling citrus sour rot and its application are disclosed by the present invention. The citrus preservative calculated by 100% total mass fraction comprises 0.05%-0.5% polyhexamethylene guanidine hydrochloride, 0.05%-0.2% of one or more selected from the group consisting of a mixture of several of the following: 0.05%-0.2% imidazole fungicidebactericide, benzimidazole fungicidebactericide, pyrimethanil, fludioxonil and [or] azoxystrobin, and 0.02%-0.15% polyethenoxy ether emulsion or quaternary ammonium salt emulsion, and the rest is water. The citrus preservative can significantly inhibit the decay of citrus fruit such as Citrus microcarpa during storage, especially the incidence of sour rot. So the commercial value of citrus is obviously increased.Type: ApplicationFiled: November 15, 2010Publication date: September 19, 2013Inventors: Xuewu Duan, Yueming Jiang, Linyan Feng, Fuwang Wu
-
Patent number: 8535698Abstract: A water dispersible granule formulation prepared by pulverized a part of active ingredients into fine particles under wet milling and pulverized another part of the active ingredients into coarse particles under dry milling, then kneading the both active ingredients for the granulation, and a process for producing the water dispersible granule formulation are disclosed. The water dispersible granule formulation according to the present invention is applicable from production of a water dispersible granule formulation comprising an active ingredient which is easily decomposed owing to environmental conditions and allows to provide the water dispersible granule formulation provided with enhanced initial and residual biological activities.Type: GrantFiled: December 30, 2010Date of Patent: September 17, 2013Assignee: Nippon Soda Co., Ltd.Inventor: Masahiro Suzuki
-
Publication number: 20130217735Abstract: Disclosed are compositions and methods of preparing compositions of active fungicidal ingredients. Also disclosed are methods of using the compositions described herein to improve fungicide penetration into the plant tissue, reduce fungicide volatility and drift, decrease water solubility of the fungicides, and introduce additional biological function to fungicides.Type: ApplicationFiled: August 12, 2011Publication date: August 22, 2013Applicants: Agri-Food and BioSciences Institute, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMAInventors: Robin D. Rogers, Louise R. Cooke
-
Publication number: 20130217660Abstract: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.Type: ApplicationFiled: May 12, 2011Publication date: August 22, 2013Inventors: Dong-Ming Shen, John S. Debenham, Thomas H. Graham, Matthew J. Clements, Yong Zhang
-
Publication number: 20130211352Abstract: The purpose of the invention is to produce an imidafenacin-containing percutaneously absorbed preparation, wherein the drug not only is not allowed to crystallize but also has adequate skin penetration. The imidafenacin-containing percutaneously absorbed preparation comprises isostearic acid and a fatty acid ester, which function as crystallization-preventing agents.Type: ApplicationFiled: October 26, 2011Publication date: August 15, 2013Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventor: Hisakazu Kurita
-
Publication number: 20130211353Abstract: Provided is a percutaneous absorption type formulation of a drug such as imidafenacin and silodosin, wherein stable absorption through the skin is realized. The percutaneous absorption type formulation containing a drug such as imidafenacin and silodosin further contains a transdermal absorption promoting agent, and fatty acid ester and/or fatty acid amide that further improve(s) the function of the transdermal absorption promoting agent.Type: ApplicationFiled: October 26, 2011Publication date: August 15, 2013Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Arata Toshimitsu, Hisakazu Kurita
-
Publication number: 20130203829Abstract: The present application is directed to novel imidazole-substituted fatty acids that have been functionalized with an alkyl triphenylphosphonium group, compositions comprising these compounds and their use as inhibitors of cytochrome c peroxidase, in particular for the treatment and prevention of apoptosis.Type: ApplicationFiled: November 13, 2012Publication date: August 8, 2013Inventors: Jeffrey Atkinson, Jeffrey Stuart, Valarian E. Kagan, Detcho A. Stoyanovsky, Michael W. Epperly, Joel S. Greenberger
-
Patent number: 8501743Abstract: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a tertiary system, in which menthol may form part of the eutectic mixture or in the eutectic mixture comprises an antidandruff agent such as ketoconazole.Type: GrantFiled: November 4, 2008Date of Patent: August 6, 2013Assignee: Conopco, Inc.Inventors: Jason Shaun Burry, Richard Livesey Evans, Caroline Alexandra Hall, Ezat Khoshdel, Colina MacKay
-
Publication number: 20130196852Abstract: The invention provides a method for preparing an improved composition comprising at least one active agent and at least one solid carrier material, wherein the active agent is dispersed through the carrier material in nano-disperse form, which method comprises the steps of: (a) forming a liquid mixture comprising the active agent, the carrier material, a stabilizing agent, a first solvent for the active agent and the stabilizing agent and, a second solvent for the carrier material, and (b) drying the liquid mixture to remove the first and second solvents to obtain a substantially solvent-free nano-dispersion of the active agent with the stabilising agent in the carrier material, wherein the stabilizing agent is capable of stabilizing the active agent in the liquid mixture during drying and in a resultant liquid nano-dispersion of the improved composition.Type: ApplicationFiled: October 4, 2011Publication date: August 1, 2013Applicant: IOTA NANOSOLUTIONS LIMITEDInventors: Steven Paul Rannard, David Duncalf, Alison Jayne Foster, James Long, Dong Wang
-
Patent number: 8486985Abstract: The invention provides methods for treating disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the invention provides methods employing well-defined N-[1-(2 and/or 3-substituted-phenyl)-alkyl]-(4,5-dihydro-1H-imidazol-2-yl)-amines and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation, such as ocular disorders, pain and central nervous system (CNS) motor disorders.Type: GrantFiled: May 11, 2009Date of Patent: July 16, 2013Assignee: Allergan, Inc.Inventors: Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh
-
Publication number: 20130158036Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: ApplicationFiled: November 1, 2012Publication date: June 20, 2013Applicant: PANMIRA PHARMACEUTICALS, LLCInventor: PANMIRA PHARMACEUTICALS, LLC
-
Publication number: 20130144264Abstract: Bioactive, hydroforming luminal liner compositions are formed of high molecular weight crystalline, absorbable copolyesters dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.Type: ApplicationFiled: January 30, 2013Publication date: June 6, 2013Inventors: Shalaby W. Shalaby, Kenneth David Gray, Georgios T. Hilas
-
Patent number: 8455497Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.Type: GrantFiled: February 12, 2009Date of Patent: June 4, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Michael R. Hale, Roger Tung, Stephen Price, Robin David Wilkes, Wayne Carl Schairer, Ashley Nicholas Jarvis, Andrew Spaltenstein, Eric Steven Furfine, Vicente Samano, Istvan Kaldor, John Franklin Miller, Michael Stephen Brieger, Ronald George Sherrill
-
Publication number: 20130131028Abstract: Described herein are methods for modulation of the activity of the carotid body that afford therapeutic benefit for sleep-related breathing disorders and related conditions.Type: ApplicationFiled: April 11, 2011Publication date: May 23, 2013Applicants: JOHNS HOPKINS UNIVERSITY, SOVA PHARMACEUTICALS, INC., THE UNIVERSITY OF CHICAGOInventors: Solomon H. Snyder, Moataz M. Gadalla, Nanduri R. Prabhakar, Gregory Stein, Gary Pace
-
Publication number: 20130122053Abstract: The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34.Type: ApplicationFiled: September 24, 2012Publication date: May 16, 2013Applicants: Trustees of Dartmouth College, Rutgers, The State University of New Jersey, The Regents of the University of California, Osteoscreen, Inc.Inventors: Trustees of Dartmouth College, Osteoscreen, Inc., The Regents of the University of California, Rutgers, The State University of new Jersey
-
Publication number: 20130123287Abstract: Providing a novel control agent for soft rot and a novel control method for the same. A compound having no antibacterial activity against Erwinia carotovora but having a control activity against fungi on soil surface, specifically containing, as the active ingredient, a fungicide comprising any of a strobilurin compound such as azoxystrobin and kresoxim-methyl, an azole compound such as triflumizol, cyazofamid, amisulbrom, and thiophanate-methyl, a carboxamide compound such as penthiopyrad and boscalid, a sulfonamide compound such as flusulfamide, an organic chlorine compound such as chlorothalonil, a dicarboximide compound such as pro-cymidone and iprodione, a phenylpyrrole compound such as fludioxonil, an anilinopyrimidine compound such as mepanipyrim, and a guanidine compound such as iminoctadine is the control agent for plant soft rot, which is applied to plant cultivation soil.Type: ApplicationFiled: July 21, 2011Publication date: May 16, 2013Applicant: ISHIHARA SANGYO KAISHA, LTD.Inventors: Koji Sugimoto, Hiroyuki Hayashi
-
Publication number: 20130095068Abstract: Provided is an imidazolylbenzene compound or salt thereof that controls HCV replication and in addition is particularly capable of strongly controlling HCV replication, and is very effective in the prevention and treatment of HCV infection when used in combination with another agent for treating HCV infection such as Interferon.Type: ApplicationFiled: June 14, 2011Publication date: April 18, 2013Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Mamoru Yanagimachi, Mitsuhiro Ino
-
Publication number: 20130089526Abstract: The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions.Type: ApplicationFiled: May 8, 2012Publication date: April 11, 2013Applicants: Trustees of Dartmouth College, National Institute of Health, Beth Israel Deaconess Medical Center, Rutgers, The State UniversityInventors: Trustees of Dartmouth College, Beth Israel Deaconess Medical Center, National Institute of Health, Rutgers, The Sstate University
-
Patent number: 8409550Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of at combination of retinoid boosters.Type: GrantFiled: June 21, 2012Date of Patent: April 2, 2013Assignee: Unilever Home & Personal Care, USA, Division of Conopco, Inc.Inventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Publication number: 20130072491Abstract: An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object is achieved by a composition that contains a compound represented by the following General Formula (I) or a salt thereof (refer to the Description for the definitions of the symbols used in the formula).Type: ApplicationFiled: August 31, 2012Publication date: March 21, 2013Applicant: Ajinomoto Co., Inc.Inventors: Reiko YASUDA, Yuzuru Eto, Yoshiro Kitahara
-
Publication number: 20130065861Abstract: The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.Type: ApplicationFiled: March 23, 2011Publication date: March 14, 2013Inventors: Tom Yao-Hsiang Wu, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Publication number: 20130065854Abstract: A composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifluoromethyl group, and one or more azole compounds selected from group (A) consisting of propiconazole, prothioconazole, triadimenol, prochloraz, penconazole, tebuconazole, flusilazole, diniconazole, bromuconazole, epoxiconazole, difenoconazole, cyproconazole, metconazole, triflumizole, tetraconazole, myclobutanil, fenbuconazole, hexaconazole, fluquinconazole, triticonazole, bitertanol, imazalil, ipconazole, simeconazole, hymexazol, etridiazole and flutriafol.Type: ApplicationFiled: April 25, 2011Publication date: March 14, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Yuichi Matsuzaki
-
Publication number: 20130052248Abstract: An item of clothing (10) for daily pharmacological treatment of a fungal infection, comprising: a textile material (20) to manage moisture when the item of clothing (10) is worn; microcapsules (30) grafted on the textile material (20); and antifungal agents encapsulated within the microcapsules (30) to pharmacologically treat the fungal infection when released from the microcapsules (30).Type: ApplicationFiled: August 26, 2011Publication date: February 28, 2013Inventors: Marcus Chun Wah YUEN, Joanne Yiu Wan YIP, Kevin CHEUK, Chi Wai KAN, Shuk Yan CHENG
-
Publication number: 20130045956Abstract: The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be provided. The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be safely administered to the patients with Hand-Foot Syndrome, and has shown the superior preventive and/or treatment effect against Hand-Foot Syndrome.Type: ApplicationFiled: March 30, 2011Publication date: February 21, 2013Inventors: Kazuhiro Ishizaka, Tadashi Nomizu, Aya Kitao
-
Publication number: 20130022660Abstract: The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.Type: ApplicationFiled: July 22, 2012Publication date: January 24, 2013Applicant: EDGE THERAPEUTICS, INC.Inventors: R. Loch Macdonald, Brian A. Leuthner
-
Publication number: 20130022564Abstract: The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug for treating various skin infections, such as fungal, bacterial, and/or viral skin infections. The formulation can include anti-infective drug, solvent vehicle, and solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained periods of time. The non-volatile solvent system can also act to plasticize the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: July 23, 2012Publication date: January 24, 2013Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20130012552Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more azole fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease.Type: ApplicationFiled: March 2, 2011Publication date: January 10, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka, Mayuko Ozawa, Atsushi Iwata
-
Publication number: 20130005739Abstract: The present invention relates to pharmaceutical compositions comprising a COS releasing compound according to formula (I) and to methods of preparing such compositions. Said pharmaceutical compositions may preferably be used for the treatment and/or the prevention of cardiovascular diseases.Type: ApplicationFiled: December 28, 2010Publication date: January 3, 2013Applicants: LUDWIG BOLTZMANN CLUSTER FUER KARDIOVASKULAERE FORSCHUNG, UNIVERSITAET WIENInventors: Thomas Erker, Gerda Brunhofer, Christian Studenik, Bruno Podesser, Gabriela Pomper
-
Publication number: 20120315233Abstract: The use of specific compounds of the Formula 1 (and also corresponding mixtures) in particular as cosmetic agents for the inhibition of the substance P-induced release of histamine from mast cells is described.Type: ApplicationFiled: June 15, 2012Publication date: December 13, 2012Applicant: SYMRISE AGInventors: Gerhard Schmaus, Holger Joppe, Martina Herrmann, Christopher Sabater-Luntzel, Tobias Vössing
-
Patent number: 8329745Abstract: Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules of the general formula: Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.Type: GrantFiled: September 6, 2011Date of Patent: December 11, 2012Assignee: Board of Regents, The University of Texas SystemInventors: Patrcik G. Harran, Michael S. Brown, Joseph L. Goldstein, Jing Yang, Tong-Jin Zhao
-
Publication number: 20120301422Abstract: The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism.Type: ApplicationFiled: January 16, 2003Publication date: November 29, 2012Inventor: Petrus Johannes Meyer
-
Patent number: 8309608Abstract: The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.Type: GrantFiled: November 2, 2004Date of Patent: November 13, 2012Assignee: Sanofi-Aventis Deutschland GmbHInventors: Andreas Zeiher, Stefanie Dimmeler, Christopher Heeschen, Hartmut Ruetten
-
Patent number: 8309589Abstract: There is provided a fluorine-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein m represents 0 or 1; n represents 0, 1 or 2; A represents an optionally substituted 5-membered aromatic heterocyclic group; R1 and R3 are independently represent an optionally substituted C1-C4 chain hydrocarbon group, —C(?G)R5, cyano, halogen or hydrogen; R2 and R4 independently represent an optionally substituted C1-C4 chain hydrocarbon group, halogen or hydrogen; Q represents a C1-C5 haloalkyl group containing at least one fluorine, or fluorine; G represents oxygen or sulfur; and R5 represents optionally substituted C1-C4 alkyl, hydroxyl, optionally substituted C1-C4 alkoxy, optionally substituted C3-C6 alkenyloxy, optionally substituted C3-C6 alkynyloxy, amino, optionally substituted C1-C4 alkylamino, optionally substituted di(C1-C4 alkyl)amino, C2-C5 cyclic amino or hydrogen.Type: GrantFiled: August 28, 2008Date of Patent: November 13, 2012Assignee: Sumitomo Chemical Company, LimitedInventors: Koji Kumamoto, Hiroyuki Miyazaki
-
Publication number: 20120276182Abstract: The present invention relates to methods for treating and completely curing fungal, yeast, and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition.Type: ApplicationFiled: July 9, 2012Publication date: November 1, 2012Inventors: James R. Baker, JR., Mary R. Flack, Susan M. Ciotti, Joyce A. Sutcliffe
-
Patent number: 8298558Abstract: A water dispersible granule formulation prepared by pulverized a part of active ingredients into fine particles under wet milling and pulverized another part of the active ingredients into coarse particles under dry milling, then kneading the both active ingredients for the granulation, and a process for producing the water dispersible granule formulation are disclosed. The water dispersible granule formulation according to the present invention is applicable for production of a water dispersible granule formulation comprising an active ingredient which is easily decomposed owing to environmental conditions and allows to provide the water dispersible granule formulation provided with enhanced initial and residual biological activities.Type: GrantFiled: October 12, 2007Date of Patent: October 30, 2012Assignee: Nippon Soda Co., Ltd.Inventor: Masahiro Suzuki
-
Publication number: 20120270901Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5, and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: December 8, 2011Publication date: October 25, 2012Applicant: Aquinox Pharmaceuticals Inc.Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
-
Patent number: 8288315Abstract: Fungicidal mixtures comprising, as active components: 1) metconazole of the formula I and 2) prochloraz of the formula II, in a synergistically effective amount, and also compositions comprising these mixtures.Type: GrantFiled: April 7, 2008Date of Patent: October 16, 2012Assignee: BASF SEInventors: Dirk Voeste, Carola Reinecke, Frank Werner, Egon Haden
-
Publication number: 20120258061Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid in combination with 0.0001% to about 50% of at combination of retinoid hoosters.Type: ApplicationFiled: June 21, 2012Publication date: October 11, 2012Applicant: CONOPCO, INC., D/B/A UNILEVERInventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Patent number: 8283376Abstract: The invention relates to the use of substituted 2-aminotetralins of general formula (I) as a medicament for the preventive treatment of Parkinson's disease.Type: GrantFiled: December 23, 2004Date of Patent: October 9, 2012Assignee: UCB Pharma GmbHInventors: Dieter Scheller, Frank Dressen
-
Publication number: 20120252820Abstract: Methods of identifying compounds that potentiate the activity of antifungal agents, potentiators identified by these methods, and methods of using potentiators to treat fungal infections are disclosed.Type: ApplicationFiled: April 22, 2009Publication date: October 4, 2012Applicant: NORTHEASTERN UNIVERSITYInventors: Kim Lewis, Michael David Lafleur
-
Publication number: 20120252776Abstract: Disclosed herein are novel C4-monomethyl triterpenoid compounds and derivatives thereof, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.Type: ApplicationFiled: March 12, 2012Publication date: October 4, 2012Inventors: Eric Anderson, Christopher F. Bender, Xiaofeng Liu, Xin Jiang, Melean Visnick
-
Publication number: 20120245138Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: May 2, 2012Publication date: September 27, 2012Applicant: ChemoCentryx, Inc.Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
-
Patent number: 8263635Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.Type: GrantFiled: June 28, 2010Date of Patent: September 11, 2012Assignee: Novartis AGInventors: Mark G. Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
-
Publication number: 20120219602Abstract: The present invention relates to methods for treating, killing, and/or inhibiting the growth of Herpes viruses in human subjects comprising topically administering to a human subject in need thereof a nanoemulsion composition having antiviral properties.Type: ApplicationFiled: February 28, 2012Publication date: August 30, 2012Inventors: Mary R. Flack, Susan Marie Ciotti, Tarek Hamouda, Joyce A. Sutcliffe, James R. Baker, JR.
-
Publication number: 20120214808Abstract: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Applicant: Prosidion LimitedInventors: Jason Bloxham, Matthew Colin Thor Fyfe, James Horswill, Revathy Perpetua Jeevaratnam, John Keily, Martin James Procter, Karen Lesley Schofield, Salam Shaaban, Simon Andrew Swain, Philippe Wong-Kai-In
-
Publication number: 20120207826Abstract: There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.Type: ApplicationFiled: October 22, 2010Publication date: August 16, 2012Inventors: Thomas Julius Borody, Soledad Carsula
-
Patent number: RE43816Abstract: A water dispersible granule formulation prepared by pulverized a part of active ingredients into fine particles under wet milling and pulverized another part of the active ingredients into coarse particles under dry milling, then kneading the both active ingredients for the granulation, and a process for producing the water dispersible granule formulation are disclosed. The water dispersible granule formulation according to the present invention is applicable for production of a water dispersible granule formulation comprising an active ingredient which is easily decomposed owing to environmental conditions and allows to provide the water dispersible granule formulation provided with enhanced initial and residual biological activities.Type: GrantFiled: October 24, 2011Date of Patent: November 20, 2012Assignee: Nippon Soda Co., Ltd.Inventor: Masahiro Suzuki